Amylyx Pharmaceuticals
Amylyx is a clinical-stage biotech company focused on treating diseases with high unmet needs, emphasizing rapid action, rigorous science, and community care. The company values innovation, curiosity, authenticity, engagement, and accountability.
Headquarters
Cambridge, Massachusetts, United States
Company Size
201-500 employees
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for diseases with high unmet needs, including Post-Bariatric Hypoglycemia (PBH), Wolfram Syndrome, and Amyotrophic Lateral Sclerosis (ALS). Its lead program, Avexitide, is being evaluated in the pivotal Phase 3 LUCIDITY clinical trial for PBH. Amylyx advances its pipeline using rigorous science, well-defined mechanistic rationale, and a strong commitment to the patient communities it serves.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Amylyx Pharmaceuticals.
68% above the average for this role
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating
4 days ago
Global QA Manager - Computer System Validation (m/w/d)
medac GmbH
Senior Validation Engineer
Verista, Inc.
Global Quality Lead Auditing Technology
City of Pierre, South Dakota
Quality Assurance – Computer System Validation (CSV)
Elanco
Director, IT Business Partner - Biopharma GXP
Nuvalent, Inc.
Computer System Validation Specialist
Validation & Engineering Group